Beam Therapeutics Inc. reported an estimated $1.25 billion in cash, cash equivalents, and marketable securities as of December 31, 2025. This figure includes $255.1 million received from the acquisition of Orbital Therapeutics by Bristol-Myers Squibb, with the potential for up to $26.3 million in additional cash pending escrow release. The company expects this financial position to fund anticipated operating expenses and capital expenditures into 2029, supporting the projected launch of risto-cel for sickle cell disease and the pivotal development of BEAM-302 in alpha-1 antitrypsin deficiency. This extended operating runway reflects a significant strengthening of Beam’s financial outlook and positions the company to execute its late-stage clinical programs and commercial transition plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623450-en) on January 11, 2026, and is solely responsible for the information contained therein.